Matinas Biopharma Holdings Inc

ASE:MTNB   3:59:45 PM EDT
0.78
+0.01 (+1.94%)
Products

Matinas Biopharma Holdings Announces Positive End Of Phase 2 Meeting With FDA For MAT9001 In Severe Hypertriglyceridemia

Published: 09/15/2020 11:28 GMT
Matinas Biopharma Holdings Inc (MTNB) - Matinas Biopharma Holdings Inc - Announces Positive End of Phase 2 Meeting With FDA for Mat9001 in Severe Hypertriglyceridemia.
Matinas Biopharma - Official Minutes of Confirmed FDA, Co Aligned on Key Next Steps for Mat9001's Phase 3 Development Program.
Matinas Biopharma Holdings Inc - on Track to Initiate Its Phase 3 Program in H1 2021.